Applications

1610 – Clostridium botulinum type A toxin-haemagglutin complex (Dysport) for the treatment of moderate to severe upper-limb spasticity due to cerebral palsy

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

The applicant seeks to change the descriptor of MBS item 18361 to include 'Clostridium Botulinum Type A Toxin-Haemagglutinin Complex (Dysport)' in the list of botulinum toxins associated with the item number. The request seeks to align the descriptor with recent changes to the wording for patients aged 2 years and older with upper limb spasticity associated with cerebral palsy, and also align the descriptor for MBS item 18361 with the PBS criteria by removing the requirement that adult cerebral palsy patients must have commenced treatment with botulinum toxin as a paediatric patient.

Service or technology in this application

Injection of Clostridium Botulinum Type A Toxin-Haemagglutinin Complex (Dysport) for the treatment of patients aged 2 years and older for upper limb spasticity associated with cerebral palsy.

Type: Therapeutic

Medical condition this application addresses

Spasticity is a chronic condition causing deformity and pain, and occurs in approximately 91% of children with cerebral palsy. Upper limb spasticity causes reduced motor function and reduced muscle strength. Spasticity is characterised by an increase in muscle tone that leads to spasms and ultimately muscle and soft tissue contracture. Contractures can eventually render the limb functionless.

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 28 to 29 July 2020